Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.
Daniel E SprattMohammed AlshalalfaNick FishbaneAdam B WeinerRohit MehraBrandon A MahalJonathan LehrerYang LiuShuang G ZhaoCorey W SpeersTodd M MorganAdam P DickerStephen J FreedlandR Jeffery KarnesSheila WeinmannElai DavicioniAshley E RossRobert B DenPaul L NguyenFelix Y FengTamara L LotanArul M ChinnaiyanEdward M SchaefferPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Leveraging large-scale transcriptomic data allowed the identification of an aggressive subtype of treatment-naïve primary prostate cancer that harbors molecular features more analogous to mCRPC. This suggests that a preexisting subgroup of patients may have tumors that are predisposed to fail multiple current standard-of-care therapies and warrant dedicated therapeutic investigation.
Keyphrases
- prostate cancer
- single cell
- radical prostatectomy
- end stage renal disease
- healthcare
- newly diagnosed
- palliative care
- rna seq
- peritoneal dialysis
- machine learning
- randomized controlled trial
- big data
- quality improvement
- electronic health record
- single molecule
- replacement therapy
- pain management
- deep learning
- chronic pain
- phase iii
- double blind
- health insurance
- placebo controlled